Prophylactic Allotopic Expression for Atherosclerosis

What I Did

I initiated a comprehensive literature search to map all 13 mitochondrial protein-coding genes with their allotopic expression status, technical barriers, and clinical programs—exactly what you requested. The search identified 10 relevant papers from the academic literature, including key work on codon optimization for allotopic expression and reviews of gene therapy strategies for mitochondrial diseases.

However, I ran into a technical snag: the full-text access for several DOIs failed, meaning I captured abstracts and excerpts but couldn't extract the detailed tables and trial data (GenSight phase info, SENS MitoSENS publications specifics, UK Biobank haplogroup effect sizes) needed to build your complete 13-gene map. I did capture one crucial finding from the accessible excerpts: codon optimization of mitochondrial protein-coding sequences for nuclear expression is a necessary and effective strategy[1], which confirms that simply moving native mtDNA sequences to the nucleus won't work—you need to re-engineer them for the nuclear genetic code.

Scientific Discoveries

No formalized scientific discoveries yet. Key Insights are shown above this message.

Current Objective & Next Steps

Current Objective: Complete the systematic 13-gene mapping by gathering comprehensive data on allotopic expression status, technical barriers, and clinical programs for each mitochondrial protein-coding gene, then validate gene selection with human deletion prevalence and UK Biobank haplogroup data.

Given the access issues, I'm refining the approach to build your complete dataset. Here's the plan for the next iteration:

1. Create the comprehensive 13-gene map – I'll search more broadly for GenSight clinical trial databases (clinicaltrials.gov registries), SENS Research Foundation publications (freely available on their website), and the specific reviews you mentioned (Lyu et al. 2025, Ball et al. 2025) to compile the table you need: Gene | Complex | Allotopic Expression Status | Technical Barriers | Clinical Program. This will give you the full landscape of which genes are technically feasible and where clinical translation is happening.

2. Validate gene targets with human deletion data – I'll search for autopsy and tissue studies that quantify which mtDNA genes are actually deleted in aged human tissues, particularly cardiovascular. This is critical because if we're proposing prophylactic allotopic expression (preventing age-related deletion pathology), we need to know whether ND5, COX1, and ATP6 are truly the highest-priority targets or if the common 4977bp deletion hits a different gene set.

3. Extract UK Biobank haplogroup effect sizes – I'll locate UK Biobank mitochondrial studies to quantify how much cardiovascular/longevity variance is explained by naturally occurring mtDNA variants. This gives us a ceiling estimate: if haplogroups (which represent small mtDNA differences) show X% effect on atherosclerosis, then fully rescuing deletion-driven dysfunction should provide at least that magnitude of benefit—probably more, since deletions are far more disruptive than haplogroup SNPs.

These three tasks together will answer your original question comprehensively and provide the evidence base to assess whether a prophylactic allotopic expression strategy targeting mtDNA deletions could meaningfully impact age-related cardiovascular pathology via the "Survival of the Slowest" → oxidative stress → LDL oxidation → atherosclerosis pathway.

Summary

I launched a systematic literature search to map all 13 mitochondrial genes and assess allotopic expression feasibility, but encountered access limitations that prevented extraction of detailed clinical trial data and UK Biobank findings. The next iteration will compile the complete 13-gene map from open-access sources (GenSight trials, SENS publications, recent reviews), validate gene targets using human deletion prevalence data, and extract UK Biobank haplogroup effect sizes to estimate the predicted impact of rendering mtDNA deletions functionally irrelevant through allotopic expression.

---

Let me know if you'd like me to proceed with this plan, or if you have feedback or want to adjust the direction!